Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ecteinascidin 770 (ET-770) inhibits U373MG cells and is a 1,2,3, 4-tetrahydroisoquinoline alkaloid with strong anticancer activity.IC50 is 4.83 nM.
产品描述 | Ecteinascidin 770 (ET-770) inhibits U373MG cells and is a 1,2,3, 4-tetrahydroisoquinoline alkaloid with strong anticancer activity.IC50 is 4.83 nM. |
靶点活性 | U373MG cells:4.83 nM |
体外活性 | ET-770 is shown to enhance anoikis response of human lung cancer H23 cells in a dose-dependent manner. Ecteinascidin 770 sensitizes the cells by activating the p53 protein, which in turn down-regulates anti-apoptotic myeloid cell leukemia sequence-1 (MCL1) and up-regulates BCL2-associated X protein (BAX) proteins. However, B-cell lymphoma-2 (BCL2) proteins are not significantly affected by Ecteinascidin 770. The anoikis sensitization of ET-770 is observed in H460 lung cancer cells.Ecteinascidin 770 induces apoptosis of U373MG cells. The IC50 concentration of ecteinascidin 770 for killing U373MG glioblastoma cells in culture by using the MTT assay is 4.83 nM by a 72 hour-treatment. The IC50 values against human cell lines HCT116, QG56, and DU145 are 0.6, 2.4, and 0.81 nM, respectively. |
别名 | Ecteinascidine 770, Et-770 |
分子量 | 770.85 |
分子式 | C40H42N4O10S |
CAS No. | 114899-80-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ecteinascidin 770 114899-80-8 Others Ecteinascidine 770 Et-770 Inhibitor inhibitor inhibit